Table 1.
Demographic and clinical characteristics of the study participants.
| Number (%) or mean ± SD | ||||||
|---|---|---|---|---|---|---|
| All (n = 60) | Placebo (n = 20) | OEA 300 mg/day (n = 20) | OEA 600 mg/day (n = 20) | P value | ||
| Male/female | 31/29 | 11/9 | 10/10 | 10/10 | 0.935 | |
|
| ||||||
| Age (years) | 68.60 ± 2.10 | 65.4 ± 3.21 | 67.2 ± 2.65 | 69.7 ± 3.09 | 0.648 | |
|
| ||||||
| BMI (kg/m2) | 26.9 ± 4.12 | 27.2 ± 3.71 | 26.4 ± 4.32 | 27.1 ± 3.45 | 0.762 | |
|
| ||||||
| Risk factors | Smoking | 34 (56.6%) | 11 (55%) | 9 (45%) | 14 (70%) | 0.275 |
| Hypertension | 51 (85%) | 16 (80%) | 17 (85%) | 18 (90%) | 0.676 | |
| Hyperlipidemia | 47 (78.3%) | 14 (70%) | 16 (80%) | 15 (75%) | 0.766 | |
| CAD | 35 (58.3%) | 17 (85%) | 12 (60%) | 16 (80%) | 0.155 | |
| Diabetes mellitus | 16 (26.6%) | 5 (25%) | 4 (20%) | 7 (35%) | 0.551 | |
| Prior stroke | 17 (28.3%) | 7 (35%) | 4 (20%) | 6 (30%) | 0.563 | |
| DVT | 6 (10%) | 1 (5%) | 2 (10%) | 2 (10%) | 0.804 | |
| SBP, mmHg | 149 ± 8.29 | 152 ± 11.01 | 149 ± 10.73 | 148 ± 12.14 | 0.742 | |
| DBP, mmHg | 87 ± 10.02 | 87 ± 8.73 | 89 ± 10.20 | 88 ± 12.65 | 0.933 | |
|
| ||||||
| Acute ischemic stroke event characteristics | NIHSS | 5.2 ± 1.26 | 5.12 ± 1.72 | 5.18 ± 1.50 | 5.26 ± 1.37 | 0.790 |
| Infarct volume (cm3) | 1.2 ± 0.87 | 1.1 ± 1.02 | 1.2 ± 0.98 | 1.4 ± 1.25 | 0.720 | |
| mRS | 2.1 ± 0.34 | 2.03 ± 0.53 | 2.12 ± 0.36 | 1.96 ± 0.27 | 0.502 | |
| DTN, hours | 8.3 ± 4.57 | 7.2 ± 5.19 | 7.9 ± 4.21 | 8.3 ± 4.71 | 0.191 | |
| Thrombolytic therapy | 27 (45%) | 9 (45%) | 8 (40%) | 10 (50%) | 0.817 | |
| Nonthrombolytic therapy | 33 (55%) | 11 (55%) | 12 (60%) | 10 (50%) | 0.817 | |
|
| ||||||
| Medications prior to admission | Antiplatelet therapy | 18 (30%) | 8 (40%) | 4 (20%) | 6 (30%) | 0.386 |
| Anticoagulation therapy | 18 (30%) | 8 (40%) | 4 (20%) | 6 (30%) | 0.386 | |
| Statin therapy | 47 (78.3%) | 14 (70%) | 16 (80%) | 15 (75%) | 0.766 | |
| ACEI therapy | 50 (83.3) | 16 (80%) | 17 (85%) | 17 (85%) | 0.877 | |
| ARB therapy | 4 (6.6%) | 1 (5%) | 2 (10%) | 1 (5%) | 0.765 | |
| BB therapy | 29 (48.3%) | 11 (55%) | 8 (40%) | 10 (50%) | 0.627 | |
| CCB therapy | 36 (60%) | 12 (60%) | 14 (70%) | 10 (50%) | 0.435 | |
| Diuretics therapy | 9 (15%) | 3 (15%) | 3 (15%) | 3 (15%) | 1.00 | |
| Insulin with oral antidiabetic therapy | 10 (16.6%) | 3 (15%) | 2 (10%) | 5 (25%) | 0.432 | |
| Oral anti diabetic therapy | 6 (10%) | 2 (10%) | 2 (10%) | 2 (10%) | 1.00 | |
|
| ||||||
| Underlying mechanism for stroke | Atherothrombotic | 33 (55%) | 12 (60%) | 10 (50%) | 11 (55%) | 0.817 |
| Cardioembolic | 9 (15%) | 3 (15%) | 2 (10%) | 4 (20%) | 0.676 | |
| Lacunar infract | 9 (15%) | 3 (15%) | 3 (15%) | 3 (15%) | 1.00 | |
| Other causes | 6 (10%) | 2 (10%) | 2 (10%) | 2 (10%) | 1.00 | |
| Undetermined | 3 (5%) | 1 (5%) | 1 (5%) | 1 (5%) | 1.00 | |
Abbreviations: BMI, body mass index; CAD, coronary artery disease; DVT, deep vein thrombosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; mRS, Modified Rankin scale; DTN, door-to-needle time; ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; BB, beta blocker; CCB, calcium channel blocker.